Potency

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Retrieved on: 
星期二, 四月 23, 2024
Sequence, Small RNA, RNA editing, Potency, Durability, Health, ...Continued, RNA, MD, Doctor of Philosophy, Weight loss, IND, CNS, Obesity, Oligonucleotide, GSK, Patient, Medicinal chemistry, MBA, Liu Wei, Clinical trial, Pharmaceutical industry

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today provided an update on its best-in-class small interfering RNA (siRNA) and RNA editing platform capabilities.

Key Points: 
  • As part of Wave’s ongoing collaboration with GSK, GSK has selected its first two programs to advance to development candidates following achievement of target validation.
  • GSK will provide an aggregate initiation payment of $12 million to Wave for these two oligonucleotide programs.
  • Under the agreement, GSK can advance up to eight programs leveraging Wave’s PRISM™ platform and multiple RNA-targeting modalities (RNA editing, splicing, siRNA, and antisense) with target validation work ongoing across multiple therapy areas.
  • Beyond these programs, our collaboration is focusing on all Wave modalities, including RNA editing.

Jennifer Baron, MD, Solves Consumer Demands with Pharma-Grade Skincare Line

Retrieved on: 
星期二, 八月 8, 2023
Cream, Geography, Magic, Caffeine, Face, Macadamia, Serum, Hyaluronic acid, Tissue hydration, Periorbital puffiness, Light, Neck, Aloe vera, American Board of Commissioners for Foreign Missions, Green tea, Antioxidant, Patient, UV, American Board of Dermatology, SAN, Potency, System, Skin, Pachycormus discolor, Cosmetics

SAN JOSE, Calif., Aug. 8, 2023 /PRNewswire/ -- In the last five years, skin care products have taken a surge of interest across all genders, generations, geographics, and sensitivities, but many consumers are still seeking an authentic, natural remedy to their skin concerns. As a solution, Jennifer Baron, M.D. has been listening to her patients one-on-one and created a line of powerful skin-saving products that are changing consumers' skin for the better.

Key Points: 
  • has been listening to her patients one-on-one and created a line of powerful skin-saving products that are changing consumers' skin for the better.
  • Dr. Baron began creating kitchen-to-face original skin creams as far back as her junior year of high school.
  • Now she creates medical grade, personally designed, humanely sourced products that are manufactured with the highest standards in South Korea.
  • skincare products are priced between $19.95 and $125, and personalized regimen bundles are priced between $197.75 and $372.25.

Ascension Healthcare Announces Positive Data from Phase 2 Study of XLR8 in Severe Haemophilia A Patients

Retrieved on: 
星期一, 十二月 12, 2022
Haemophilia, Bleeding, Use, Prevalence, FDA, Factor VIII, University College London, Gold, VIII, PEGylation, Osteoarthritis, Coronavirus Scientific Advisory Board (Turkey), Fibrinolysis, Potency, Haemophilia A, History, Standard of care, XLR8, Risk, Male, Ascension, Patient, Vaccine, Pharmaceutical industry, Birth control

Haemophilia A patients lack sufficient factor VIII clotting factors which leaves them at risk of uncontrolled bleeding.

Key Points: 
  • Haemophilia A patients lack sufficient factor VIII clotting factors which leaves them at risk of uncontrolled bleeding.
  • This trial was designed to demonstrate that administration of PEGLip, following a normal dose of prophylactic, standard half-life FVIII in severe, non-inhibitor Haemophilia A patients can both enhance clotting activity and extend the dosing interval beyond FVIII administered alone.
  • Results from the study demonstrated that clotting activity was significantly improved at certain time points over baseline and over injection of FVIII alone.
  • The therapy is primarily aimed at f severe patients who are receiving standard of care prophylaxis with intravenous FVIII, where the adjuvant will extend their FVIII dosing interval, thereby improving compliance.

Ascension Healthcare to Present Positive Phase 2 Data on Two Haemophilia Programmes at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
星期四, 十一月 3, 2022
Fibrinolysis, University College London, Company, Male, 2021 Essex County Council election, Society, Ascension, Bleeding, ASH, Coronavirus Scientific Advisory Board (Turkey), Use, Potency, VIII, XLR8, Haemophilia, Risk, Prevalence, Selective serotonin reuptake inhibitor, Patient, Osteoarthritis, Pharmaceutical industry, Dentistry

The ASH annual meeting will take place from the10-13 December 2022 in New Orleans, Louisiana and virtually.

Key Points: 
  • The ASH annual meeting will take place from the10-13 December 2022 in New Orleans, Louisiana and virtually.
  • Biresh Roy, Chief Executive Officer at Ascension commented: We are immensely privileged to have been selected to present our successful Phase 2 SelectAte and XLR8 programmes at ASH, a world leader insupporting and promulgating clinical and scientific developments in haematology.
  • This is a large market that is, at present, not served by a safe, convenient, inexpensive prophylactic replacement FVIII treatment.
  • XLR8 is a form of PEGLip administered as an adjuvant to patients who already have some circulating FVIII.

GemmaCert Strengthens IP with New US Patent for Cannabis Testing

Retrieved on: 
星期二, 十二月 7, 2021
USPTO, Patent, Technology, Cannabis, Breeding, Leadership, Eleazar Sukenik, Hebrew University of Jerusalem, Tissue (biology), United States Patent and Trademark Office, Industry, NIR, Machine learning, Partner, TEL, Quality, Potency, Data science, Drug

TEL AVIV, Israel, Dec. 7, 2021 /PRNewswire/ --GemmaCert Ltd. today announced the expansion of its patent portfolio, demonstrating its ongoing commitment to innovation and leadership of the cannabis testing industry.

Key Points: 
  • TEL AVIV, Israel, Dec. 7, 2021 /PRNewswire/ --GemmaCert Ltd. today announced the expansion of its patent portfolio, demonstrating its ongoing commitment to innovation and leadership of the cannabis testing industry.
  • Earlier it received a notice of allowance by the United States Patent and Trademark Office (USPTO) for Testing Quality and Potency of Plant Material.
  • The booming demand for cannabis is driving the need for real-time quality control testing across the supply chain.
  • GemmaCert continues to innovate to support cannabis industry professionals seeking accurate, easy-to-use testing solutions for breeding, grow monitoring, optimal harvest timing, product quality management, ensuring accurate labels, and pricing.

Early Results of BetterLife Preclinical Study Showing AP-003 (rhIFNa2b) has Similar Potent Efficacy Against Different Variants of COVID-19

Retrieved on: 
星期四, 七月 15, 2021
Antiviral drugs, Cytokines, Health sciences, Zoonoses, Interferon, Branches of biology, Medical specialties, COVID-19, Potency

Early data show potent and similar anti-viral activity against the COVID-19 Wuhan reference strain (EC50=0.51), Alpha (B.1.1.7, UK, EC50=1.26) and Beta (B.1.351, South Africa, EC50=0.25) variants.

Key Points: 
  • Early data show potent and similar anti-viral activity against the COVID-19 Wuhan reference strain (EC50=0.51), Alpha (B.1.1.7, UK, EC50=1.26) and Beta (B.1.351, South Africa, EC50=0.25) variants.
  • Further studies are ongoing to validate these early results and to test AP-003 activity against Gamma (Brazil), Delta (India) and Lambda (Peru) variants.
  • The rhIFN2b, a Type I interferon, is a naturally occurring protein integral to the bodys first line of anti-viral defenses.
  • The broad mechanism of action of interferon is such that our scientists hypothesized it could be equally effective against different variants.

Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

Retrieved on: 
星期三, 六月 9, 2021
European Association for the Study of the Liver, Potency, Reaction inhibitor

During the meeting, data from Assembly Bios three core inhibitor programs, vebicorvir (VBR), ABI-H2158 (2158) and ABI-H3733 (3733), will be featured in an oral presentation and two poster presentations.

Key Points: 
  • During the meeting, data from Assembly Bios three core inhibitor programs, vebicorvir (VBR), ABI-H2158 (2158) and ABI-H3733 (3733), will be featured in an oral presentation and two poster presentations.
  • Posters are expected to be made available to conference registrants through the online EASL portal at the start of the meeting on the morning of Wednesday, June 23, 2021.
  • The next-generation compounds 2158 and 3733 show enhanced potency and exposures that cover cccDNA prevention at significant multiples above protein-adjusted EC50 at Cmin.
  • Overall, most patients (78%) did not have detectable core inhibitor substitutions; for patients harboring a core inhibitor substitution (22%), no enrichment compared to baseline was observed after treatment was removed.

LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States

Retrieved on: 
星期一, 二月 22, 2021
Cardiology, Biotechnology, Diabetes, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Medical specialties, Companies, Economy of South Korea, AOC3, LG Chem, Non-alcoholic fatty liver disease, Steatohepatitis, LG Corporation, Potency, Hepatitis, LG Chem Life Sciences, TransThera Biosciences

LG Chem Life Sciences (LG Chem) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.

Key Points: 
  • LG Chem Life Sciences (LG Chem) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
  • LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (TransThera), a clinical-stage biotechnology company based in Nanjing, China.
  • LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH).
  • LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally.

Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat

Retrieved on: 
星期三, 十一月 18, 2020
Health, Infectious diseases, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Sarbecovirus, Respiratory diseases, Zoonoses, Bat virome, Potency, Severe acute respiratory syndrome, Infectious diseases

Adagio expects its half-life engineered version of ADG2, called ADG20, to enter clinical studies in early 2021.

Key Points: 
  • Adagio expects its half-life engineered version of ADG2, called ADG20, to enter clinical studies in early 2021.
  • All of the antibodies currently in clinical development trade-off breadth for potency.
  • They either show broad activity against other sarbecoviruses but lack neutralization potency, or they show high neutralization potency against SARS-CoV-2 but lack activity against other coronaviruses.
  • ADG20 was designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability.

Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristem’s PLX Cells

Retrieved on: 
星期二, 三月 17, 2020
Pluristem Therapeutics, Technion – Israel Institute of Technology, RTT, Medical specialties, Autoimmune diseases, PLX, Sjögren syndrome, Potency, Medicine, Organ systems

Pluristem has not yet submitted any such request for treatment of a specific COVID-19 patient, and there is no assurance that any such request will be approved by Israeli Ministry of Health.

Key Points: 
  • Pluristem has not yet submitted any such request for treatment of a specific COVID-19 patient, and there is no assurance that any such request will be approved by Israeli Ministry of Health.
  • PLX cells are available off-the-shelf and once commercialized, can be manufactured in large scale quantities, offering a key advantage in addressing a global pandemic.
  • Accordingly, PLX cells may potentially reduce the incidence and\or severity of COVID-19 pneumonia and pneumonitis leading hopefully to a better prognosis for the patients.
  • Clinical data using PLX cells demonstrated the strong immunomodulatory potency of PLX cells in patients post major surgery.